Columbia Laboratories to Discuss Fourth Quarter and Year End 2005
Financial Results on March 7, 2006 Conference Call
LIVINGSTON, NJ – February 24, 2006 - Columbia Laboratories, Inc. (NASDAQ: CBRX) will hold a conference call on March 7, 2006 to review and discuss financial results of the fourth quarter and year ended December 31, 2005. The call will be hosted by Robert Mills, Columbia’s President and Chief Operating Officer, and David Weinberg, Chief Financial Officer.
| Access information | |
| Date: | Tuesday, March 7, 2006 |
| Time: | 11:00 AM ET |
| U.S./Canada dial-in number: | (866) 713-8395 |
| International dial-in number: | (617) 597-5309 |
| Participant passcode: | 62581078 |
| Live webcast: | www.columbialabs.com, under the events tab |
Replay Access Information
A recording of the conference call will be available two hours after completion until March 14, 2006 at 11:59 PM ET at (888) 286-8010 (U.S.) and (617) 801-6888 (International). The replay password is 68735406. The webcast will be archived for on-demand listening for one year on Columbia Laboratories website, www.columbialabs.com.
About Columbia Laboratories, Inc.
Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to the development and commercialization of women's health care and endocrinology products. Columbia markets Prochieve® 8% (progesterone gel) for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency, and Prochieve® 4% (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets Striant® (testosterone buccal system) for the treatment of hypogonadism in men. Columbia's products and product candidates utilize the Company's bioadhesive drug delivery technology, which is able to deliver a broad range of compounds, including peptides, across many of the body’s mucosal surfaces to address numerous therapeutic areas. The Company is investigating the potential utility of Prochieve® 8% in the prevention of preterm birth and developing a vaginally-administered lidocaine product to prevent and treat dysmenorrhea and pelvic pain. For more information, please visit www.columbialabs.com.
Striant® and Prochieve® are registered trademarks of Columbia Laboratories, Inc.
###